Landmark research has demonstrated that early screening for a severe muscle wasting disease at birth not only saves lives but also reduces healthcare costs for the NHS. The Mirror is advocating for the nationwide implementation of a simple £5 blood test for spinal muscular atrophy (SMA) in newborns, supported by findings from an Oxford University study. Published in the esteemed Lancet medical journal, the study revealed that 507 infants have been born with SMA in the UK since 2019. The availability of treatments on the NHS that can cure the condition if administered at birth highlights the importance of early screening.
Without newborn screening in the UK, infants with SMA were not diagnosed until around six months of age, leading to severe outcomes such as the inability to walk, reliance on breathing support, and the need for feeding tubes. In contrast, in southern Belgium where SMA screening is conducted at birth, all SMA babies survived without requiring breathing support or feeding tubes.
A study authored by Professor Laurent Servais emphasized the significant impact of the UK’s decision against implementing an SMA newborn screening program. The comparison between the UK and southern Belgium serves as a representative example of the positive outcomes associated with early screening for SMA. The study also highlighted the cost disparity in supporting SMA babies in the UK compared to those identified through newborn screening.
The Mirror has been campaigning for the inclusion of SMA screening in the NHS newborn heel prick test, aligning with practices in other developed nations. Stories like that of Ezra Thorman underscore the importance of timely diagnosis and treatment for SMA to prevent irreversible damage and disability.
Pharmaceutical company Novartis estimates that delayed diagnoses leave 33 UK babies in wheelchairs annually due to SMA. The genetic fault in SMA patients inhibits the production of SMN protein, leading to nerve cell degeneration and muscle weakness.
While the UK National Screening Committee initially rejected adding SMA to the newborn screening program in 2018, recent developments have seen the availability of innovative treatments on the NHS. However, the committee’s decision to conduct further research and pilot screening in select areas delays the nationwide rollout of SMA screening until at least 2031. In contrast, NHS Scotland has decided to proceed with newborn SMA screening from the spring.
Government officials have expressed commitment to improving early diagnosis and treatment access for children with SMA. Efforts are underway to conduct a large-scale study into newborn screening for SMA to enhance healthcare outcomes for affected infants.